Ibex Medical Analytics announced today that it received CE mark approval for its Galen gastric cancer detection solution.
Tel Aviv, Israel-based Ibex uses artificial intelligence (AI) and machine learning technology to power its Galen platform for cancer diagnostics based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology. Galen won CE mark for detecting breast cancer in 2021.
Ibex designed the first-of-its-kind solution as part of the Galen suite to implement AI for the diagnosis of gastric biopsies. The integrated diagnostic solution supports pathologists in the detection of gastric cancer, H. pylori and other important clinical findings while enabling shorter turnaround times and optimized diagnostic workflows.
CE mark approval comes on the heels of results from a blinded, multi-site clinical study at Medipath in France and Maccabi Healthcare Services in Israel in which Galen Gastric demonstrated high accura…